Business Lead, AI-native End Point Generation

Job Description Business Lead, AI-native End Point Generation Takeda is transforming how medicines are discovered by building a new Research engine where AI, advanced data platforms, and laboratory automation are embedded directly into how scientists design and discover molecules, run experiments, and make decisions. Our Labs of Tomorrow vision connects computational science, scientific data, and automated experimental workflows into a closed-loop discovery engine that will enable us to design smarter studies, shorten learning cycles, and deliver clearer evidence earlier in discovery with the ultimate goal of discovering differentiated medicines for patients.

The Business Lead, AI-native Endpoint Generation is central to realizing this vision. The scientist will be responsible for Takeda's next-generation endpoint generation AI-native software product: owning the scientific vision, customer experience, product strategy, roadmap, adoption, and ultimately the value it creates for our drug discovery. The Business Lead will define and answer what Takeda's interface to the external scientific world should be and how in vivo researchers can better plan and execute studies in a future where AI agents, predictive models, and automated experimentation are the basis of drug discovery, and where every result generated by a partner returns with the protocol, conditions, provenance, and metadata that make it usable, comparable, and ready to inform the next decision.

Our ambition is for this product to become the primary environment through which Takeda scientists commission work across our partner network and through which the evidence it produces enters our scientific data foundation complete and contextualized.

Purpose The Business Lead, AI-native Endpoint Generation is a foundational leadership role, acting as the as the owner and of Takeda's Endpoint Generation product family, an integrated family of capabilities spanning the request, execution, and return of experimental data generated in external laboratories and through in vivo research. The role refines the strategic vision for future-state AI-native Endpoint Generation Labs of Tomorrow capabilities and drives its translation into AI-enabled discovery workflows, product direction, adoption, and measurable scientific and business value by working with both relevant internal and external stakeholders.

The successful candidate will lead this portfolio as a business owner on the side of the internal customer, combining deep experience in externalized and in vivo data generation with computational, data, and technology fluency to ensure that the products built are science-first, grounded in real discovery and testing workflows, and capable of delivering decision-ready data to the project teams that depend on it.

Your customers will be Takeda's in vivo pharmacologists, DMPK and safety scientists, assay and screening scientists, study directors, externalization and outsourcing leads, and the discovery project teams that commission the work. The role carries sufficient technical fluency to provide informed direction on the strategic technology choices underpinning the product family, at the level of intent and trade-off rather than detailed evaluation or execution.

This is a unique opportunity for an exceptional leader who can combine deep understanding of externalized and in vivo experimental data generation with strong computational, data, and technology fluency, and who will ensure that the applications developed are scientifically grounded, technically actionable, adoptable by end users, and aligned with Takeda's business priorities. This role operates at the program leadership level, collaborating directly with Takeda's “Labs of Tomorrow”…